AACR Meeting Abstracts
HOME HELP FEEDBACK HOW TO CITE ABSTRACTS ARCHIVE CME INFORMATION SEARCH
Cancer ResearchClinical Cancer Research
Cancer Epidemiology Biomarkers & PreventionMolecular Cancer Therapeutics
Molecular Cancer ResearchCancer Prevention Research
Cancer Prevention Journals PortalCancer Reviews Online
Annual Meeting Education BookMeeting Abstracts Online
 QUICK SEARCH:   [advanced]




This Article
Services
Right arrow Similar articles in this journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, I. P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lee, I. P.
[Proc Amer Assoc Cancer Res, Volume 46, 2005]


Prevention Research 9: Prevention of Breast, Prostate, and Skin Cancer

Abstract #4277

Chemoprevention of MNU-induced mammary tumorigenesis in SD-rats by 1SY16 isolated from Agaricus blazei Murill K

Insu P. Lee

Kanazawa University, Kanazawa, Japan

Previously, we have demonstrated that a low molecular fraction 1SY16 (~500 dalton) isolated from Agaricus blazeiMurill K was found to be a very effective chemopreventive agent against NNK-, urethane or AOM-induced pulmonary adenoma, or colon ACF and colon carcinoma. Furthermore, chemopreventive effects of 1SY16 was closely associated with inhibition of cell cycle gene during the tumorigenesis. Present study was undertaken to evaluate whether chemopreventive effects of 1SY16 can be also demon-strated in MNU-induced mammary tumorigenesis. For the 1SY16 dose responsive effects were determined by treating 4 experimental groups, consisted of control, experimental group each receiving a single daily dose of 100, 200, or 400 mg 1SY16/kg bw for 15 days, immediately following a single administration of MNU via tail vein. To determine the stage specific chemopreventive effects of 1SY16 during the course of MNU-induced mammary tumorigenesis, 5 experimental groups, consisting of control, and 1SY16 treatment groups (200mg 1SY16/kg bw./day for the first, 2nd, 3rd, and 4th months after initiation. The results demonstrated that mammary tumor incidence in the 100, 200, or 400mg 1SY16/kg b.w./15 days groups were 22 (p<0.05), 43 (p<0.001), and 55 (p<0.01)%, respectively. Concomitantly, dose dependent inhibition was also reflected in both cyclin D1 expression (90, 75, and 58% of control) and PCNA expression (92,73, and 68% of control) in mammary tumors. Chemopreventive effects of 1SY16 at different stages of tumorigenesis were 60 (p<0.05), 65 (p<0.05), 54 (p<0.05), and 28 (0.01)% of control, respectively. Furthermore, the mean mammary tumor mass during different stages of mammary tumorigenesis were 26(p<0.05), 46, 54, and 14(p<0.05)%, respectively. In conclusion, from these experimental results together with previously published data demonstrated that 1SY16 appears to be a very potent multipotential chemopreventive agent.







HOME HELP FEEDBACK HOW TO CITE ABSTRACTS ARCHIVE CME INFORMATION SEARCH
Cancer ResearchClinical Cancer Research
Cancer Epidemiology Biomarkers & PreventionMolecular Cancer Therapeutics
Molecular Cancer ResearchCancer Prevention Research
Cancer Prevention Journals PortalCancer Reviews Online
Annual Meeting Education BookMeeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.